Clinical Trial News and Research

RSS

Human Gene Therapy highlights new advances in human retinal disease

Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Dead skin donors come to the aid of a 92 year old with severe skin ulcers

A great grandmother is the first person in Britain to have a wound healed using skin from dead donors.

9 May 2012

Sildenafil may improve cardiac function in children, young adults with single ventricle defects

Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle heart disease palliation.

9 May 2012

Viewpoints: Taking aim at 'superbugs'; Friending organ donations; Ariz. and Kansas abortion efforts hurt women

In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Vascular Closure Systems completes FastSeal Phase I FIH clinical trial

The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.

9 May 2012

GenMark Diagnostics first quarter revenues increase to $2.2M

GenMark Diagnostics, Inc. today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

Covidien to unveil new OneShot renal denervation system at EuroPCR congress

Covidien, a leading global provider of healthcare products, will unveil its new OneShot renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company's broad and growing vascular therapies portfolio, the OneShot system is designed to treat patients with hypertension who are not responsive to traditional medical therapy.

8 May 2012

Meningitis B vaccine on the horizon

Meningitis B is particularly dangerous for children, leading to 120 deaths in the UK every year. There are around 1,200 new cases of meningitis B every year. Around 1 in 10 victims die and another 15 per cent are left with permanent disabilities - often limbs have to be amputated due to blood poisoning. The infection causes inflammation of the membranes surrounding the spinal cord and brain. Symptoms include a severe headache, vomiting, a rash, sensitivity to light and a stiff neck.

8 May 2012

Can curry really be beneficial for cancer?

Curcumin is found in the spice turmeric has been linked to a range of health benefits. Studies have already shown that it can beat cancer cells grown in a laboratory and benefits have been suggested in stroke and dementia patients as well. Cucurmin, which acts as an antioxidant and has anti-inflammatory properties, has traditionally been used as an alternative remedy for liver disease, digestive disorders, acne and a range of allergies. Some studies have shown it may slow the spread of cancer, boost the effectiveness of chemotherapy and protect healthy cells from the effects of radiotherapy.

8 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Pall in-line filters can reduce severe complications, length of hospital stay in PICU

A recently published clinical study on infusion therapy indicates in-line filters from Pall Corporation can reduce severe complications and the length of a patient's stay in the pediatric intensive care unit.

From Pall Corporation 8 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Oncothyreon first quarter net income increases to $9.7 million

Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.

8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Clinverse closes $3.8 million Series B round of funding

Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical trials, announced today that it has closed a $3.8 million Series B round of funding led by Hatteras Venture Partners of Durham, NC. Vital Financial of Bethesda, MD, also participated in this funding round.

8 May 2012